Company intelligence / Profile preview

Peter Baum

Seattle / Bellevue, Washington, United Statespeterbaum.com ↗

Ownership: Private
Development stage: Other

Overview

Silverback Therapeutics develops tumor-targeted immunotherapies using its ImmunoTAC platform. Its lead candidate, SBT6050, is a HER2-directed monoclonal antibody conjugated to a TLR8 agonist. Preclinical data show potent anti-tumor immune activity with minimal peripheral toxicity. A first-in-human study in patients with HER2-expressing solid tumors was expected to begin in 2020.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodySmall moleculeAntibody-drug conjugate
Industry: Biotech

Partnerships

OrbiMed AdvisorsCelgene Corporation

Beyond the preview

Go deeper on Peter Baum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peter Baum.

Explore the full profile